Eliana Merle
Stock Analyst at UBS
(3.06)
# 1,388
Out of 4,983 analysts
98
Total ratings
45.21%
Success rate
1.6%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Eliana Merle
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BBIO BridgeBio Pharma | Maintains: Buy | $72 → $82 | $51.49 | +59.25% | 4 | Sep 12, 2025 | |
| GOSS Gossamer Bio | Upgrades: Buy | $1.25 → $9 | $3.20 | +181.25% | 3 | Sep 10, 2025 | |
| ALT Altimmune | Maintains: Buy | $26 → $24 | $3.63 | +561.16% | 2 | Aug 13, 2025 | |
| RAPT RAPT Therapeutics | Maintains: Neutral | $8 → $9 | $17.63 | -48.95% | 4 | Aug 12, 2025 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Buy | $458 → $523 | $427.05 | +22.47% | 5 | Aug 12, 2025 | |
| ANAB AnaptysBio | Maintains: Neutral | $18 → $20 | $19.39 | +3.15% | 5 | Aug 12, 2025 | |
| ASND Ascendis Pharma | Maintains: Buy | $306 → $307 | $197.24 | +55.65% | 2 | Aug 8, 2025 | |
| BMRN BioMarin Pharmaceutical | Maintains: Buy | $113 → $114 | $53.94 | +111.35% | 3 | Aug 5, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $403 → $550 | $461.24 | +19.24% | 3 | Aug 1, 2025 | |
| SRPT Sarepta Therapeutics | Downgrades: Neutral | $45 → $12 | $18.10 | -33.70% | 1 | Jul 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $4 → $8 | $2.62 | +205.34% | 1 | Jul 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $12 → $5.5 | $5.35 | +2.80% | 3 | Jun 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $74 → $21 | $7.64 | +174.87% | 6 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $72 → $70 | $48.78 | +43.50% | 3 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $78 → $70 | $24.84 | +181.80% | 7 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $44 | $23.82 | +84.72% | 8 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $25 → $38 | $7.97 | +376.79% | 3 | Jan 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $42 → $109 | $42.60 | +155.87% | 4 | Jan 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $5 → $2.2 | $1.42 | +54.93% | 4 | Jan 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $65 → $71 | $44.70 | +58.84% | 2 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $28 | $12.36 | +126.54% | 1 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $6.20 | +93.55% | 1 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $3 | $5.32 | -43.61% | 1 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $97 → $131 | $99.26 | +31.98% | 6 | Sep 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $3 → $5 | $9.33 | -46.41% | 3 | Apr 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $19 → $18 | $7.30 | +146.58% | 2 | Mar 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $45 → $42 | $14.47 | +190.26% | 4 | May 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $22 | $6.47 | +240.03% | 1 | Oct 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $51 → $47 | $9.26 | +407.56% | 1 | Jun 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $8.01 | +99.75% | 2 | May 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $192 → $134 | $32.02 | +318.49% | 3 | Aug 19, 2020 |
BridgeBio Pharma
Sep 12, 2025
Maintains: Buy
Price Target: $72 → $82
Current: $51.49
Upside: +59.25%
Gossamer Bio
Sep 10, 2025
Upgrades: Buy
Price Target: $1.25 → $9
Current: $3.20
Upside: +181.25%
Altimmune
Aug 13, 2025
Maintains: Buy
Price Target: $26 → $24
Current: $3.63
Upside: +561.16%
RAPT Therapeutics
Aug 12, 2025
Maintains: Neutral
Price Target: $8 → $9
Current: $17.63
Upside: -48.95%
Madrigal Pharmaceuticals
Aug 12, 2025
Maintains: Buy
Price Target: $458 → $523
Current: $427.05
Upside: +22.47%
AnaptysBio
Aug 12, 2025
Maintains: Neutral
Price Target: $18 → $20
Current: $19.39
Upside: +3.15%
Ascendis Pharma
Aug 8, 2025
Maintains: Buy
Price Target: $306 → $307
Current: $197.24
Upside: +55.65%
BioMarin Pharmaceutical
Aug 5, 2025
Maintains: Buy
Price Target: $113 → $114
Current: $53.94
Upside: +111.35%
Alnylam Pharmaceuticals
Aug 1, 2025
Maintains: Buy
Price Target: $403 → $550
Current: $461.24
Upside: +19.24%
Sarepta Therapeutics
Jul 21, 2025
Downgrades: Neutral
Price Target: $45 → $12
Current: $18.10
Upside: -33.70%
Jul 15, 2025
Maintains: Buy
Price Target: $4 → $8
Current: $2.62
Upside: +205.34%
Jun 26, 2025
Downgrades: Neutral
Price Target: $12 → $5.5
Current: $5.35
Upside: +2.80%
May 15, 2025
Maintains: Buy
Price Target: $74 → $21
Current: $7.64
Upside: +174.87%
May 13, 2025
Maintains: Buy
Price Target: $72 → $70
Current: $48.78
Upside: +43.50%
May 2, 2025
Maintains: Buy
Price Target: $78 → $70
Current: $24.84
Upside: +181.80%
Apr 29, 2025
Initiates: Overweight
Price Target: $44
Current: $23.82
Upside: +84.72%
Jan 31, 2025
Maintains: Buy
Price Target: $25 → $38
Current: $7.97
Upside: +376.79%
Jan 31, 2025
Maintains: Buy
Price Target: $42 → $109
Current: $42.60
Upside: +155.87%
Jan 28, 2025
Maintains: Neutral
Price Target: $5 → $2.2
Current: $1.42
Upside: +54.93%
Jan 8, 2025
Maintains: Buy
Price Target: $65 → $71
Current: $44.70
Upside: +58.84%
Jan 7, 2025
Initiates: Buy
Price Target: $28
Current: $12.36
Upside: +126.54%
Nov 12, 2024
Initiates: Buy
Price Target: $12
Current: $6.20
Upside: +93.55%
Nov 12, 2024
Initiates: Neutral
Price Target: $3
Current: $5.32
Upside: -43.61%
Sep 18, 2024
Maintains: Neutral
Price Target: $97 → $131
Current: $99.26
Upside: +31.98%
Apr 4, 2024
Maintains: Neutral
Price Target: $3 → $5
Current: $9.33
Upside: -46.41%
Mar 27, 2024
Maintains: Buy
Price Target: $19 → $18
Current: $7.30
Upside: +146.58%
May 19, 2023
Maintains: Buy
Price Target: $45 → $42
Current: $14.47
Upside: +190.26%
Oct 13, 2022
Initiates: Buy
Price Target: $22
Current: $6.47
Upside: +240.03%
Jun 23, 2022
Maintains: Buy
Price Target: $51 → $47
Current: $9.26
Upside: +407.56%
May 21, 2021
Initiates: Buy
Price Target: $16
Current: $8.01
Upside: +99.75%
Aug 19, 2020
Maintains: Neutral
Price Target: $192 → $134
Current: $32.02
Upside: +318.49%